Medical AI company Mediwhale is accelerating its push into the global digital healthcare market with its AI-powered retinal analysis technology. The company is strengthening its presence by securing additional European medical device certification for cardiovascular risk prediction, raising new investment capital, and advancing preparations for an initial public offering (IPO).
According to industry sources on June 1, Mediwhale’s AI-based retinal analysis solution, Dr.Noon, recently obtained additional medical device certification in Europe for cardiovascular disease risk prediction.
Dr.Noon analyzes retinal images using artificial intelligence to assess the risk of cardiovascular and chronic diseases. The technology is designed to predict disease risk through a non-invasive process without requiring blood tests or CT scans.
Mediwhale is expanding beyond its traditional ophthalmology-focused technology into broader disease prediction applications, including cardiovascular and metabolic disorders. Demand for AI-based risk prediction technologies is growing as the global healthcare industry increasingly emphasizes prevention and early diagnosis.
While many medical AI companies remain focused on image interpretation and diagnostic assistance, Mediwhale is targeting the emerging field of disease risk prediction.
Industry observers note that Mediwhale’s strategic direction aligns with broader trends in the global digital healthcare market.
Investor sentiment has also been favorable. Mediwhale recently secured approximately $14.6 million in Series C funding, underscoring confidence in the company’s growth potential.
The company plans to use the proceeds to expand global regulatory approvals, strengthen overseas operations, and enhance research and development capabilities. The latest funding round is also expected to accelerate preparations for an IPO.
Mediwhale is also seeking to expand its domestic commercial footprint through a partnership with Dong-A ST. By leveraging Dong-A ST’s network of hospitals and clinics, the company plans to broaden adoption of its solutions among healthcare providers.
“Medical AI is increasingly shifting beyond image interpretation toward predictive and management platforms that can be used directly in clinical practice,” an industry official said. “As regulatory frameworks for digital healthcare continue to mature in the United States and Europe, the market for AI-based preventive and predictive medical devices is expanding rapidly.”
The official added that Mediwhale is strengthening its strategy to secure both technological competitiveness and commercialization capabilities.
